NBIXBiotech: neurology, psychiatry and endocrine medicines
Neurocrine Biosciences
- Price
- $150.57
- Intrinsic value
- Intrinsic value from an AI estimate
- Discount category
- Below intrinsic value (AI estimate)
- Analysts
- Very bullish
- Next earnings
- Feb 2 · · estimated
- Pick status
- Top pick
In short
- Thesis
- The market fears that Medicare price rules and competition will cut the INGREZZA profit, and steady INGREZZA sales with fast CRENESSITY and VYKAT XR growth and good Phase 3 results in 2027 can lift its value.
- Gap
- Can close. The 2027 guidance in early 2027 and the Phase 3 results during 2027 show within about a year whether growth continues beyond INGREZZA.
Company guidance: 2026 INGREZZA net sales $2.900 to $2.925 billion; non-GAAP R&D $1,140 to $1,190 million; non-GAAP SG&A $1,290 to $1,310 million (, Q3 2026 release (8-K))
Price history
About
Neurocrine Biosciences (NBIX) is a US biopharmaceutical company that develops and sells medicines for neurological, psychiatric and endocrine disorders. INGREZZA (valbenazine) treats tardive dyskinesia and chorea associated with Huntington's disease. CRENESSITY (crinecerfont) treats classic congenital adrenal hyperplasia. VYKAT XR (diazoxide choline) treats hyperphagia in Prader-Willi syndrome.
Neurocrine got VYKAT XR when it bought Soleno Therapeutics on May 18, 2026. AbbVie sells two medicines from Neurocrine research for endometriosis and uterine fibroids. Total revenue was $1,123 million in Q3 2026, and INGREZZA was $801 million of it.
Thesis
Investors give Neurocrine a moderate multiple because most of its profit still comes from one medicine. INGREZZA was $801 million of $1,123 million of revenue in Q3 2026. Its competitor AUSTEDO gets a negotiated Medicare price from 2027, which can add price pressure on INGREZZA. INGREZZA can itself be selected for Medicare price negotiation in 2027, with a new price from 2029, and generic versions can enter from March 1, 2038.
Neurocrine also spent about $2.9 billion in cash on Soleno, and its research costs rise for two Phase 3 programs. The AI estimate assumes revenue of about $4.9 billion in 2027. For the price to rise, three things must be true. INGREZZA must keep volume growth and a stable net price in 2027.
CRENESSITY and VYKAT XR must keep growing from $211 million and $107 million a quarter in Q3 2026. The Phase 3 studies of osavampator in major depressive disorder and direclidine in schizophrenia must give good results in 2027. The R&D Day on December 15, 2026, the Q4 2026 results with the 2027 guidance in early 2027, and the Phase 3 results during 2027 are the next tests.
Valuation
AI estimate, checked by Kevin. How it is made
Show the method
The intrinsic value for Neurocrine Biosciences is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Neurocrine with the SEC. The method is a multiple of 2027 earnings per share after stock-based compensation, plus net cash per share.
The Q3 2026 release of November 2, 2026 (Form 8-K) gives total revenue of $1,123 million for Q3 2026: INGREZZA $801 million, CRENESSITY $211 million and VYKAT XR $107 million. It raises the 2026 INGREZZA guidance to $2,900 to $2,925 million, and it gives 2026 non-GAAP R&D of $1,140 to $1,190 million and non-GAAP SG&A of $1,290 to $1,310 million. Stock-based compensation was $54.3 million in Q3 2026. The estimate counts it as a cost.
It leaves out the amortization of the VYKAT XR rights and the costs of the Soleno purchase, because the purchase price is already paid. The Q3 2026 10-Q gives cash, cash equivalents and marketable securities of $790 million and no borrowings at September 30, 2026, and 101,218,643 shares outstanding at October 26, 2026. The estimate uses the diluted weighted average of 105.2 million shares in Q3 2026, so net cash is $7.51 per share. The 2027 revenue, the operating margins after stock-based compensation, a tax rate of 21%, the multiples and the weights are assumptions.
The low case assumes revenue of $4,600 million and a margin of 30%, because INGREZZA loses net price after the negotiated Medicare price of AUSTEDO starts in 2027, at 12 times. It gives $131.87 per share. The base case assumes $4,900 million and 35%, at 14 times. It gives $187.81 per share.
The high case assumes $5,200 million and 38%, with faster growth of CRENESSITY and VYKAT XR, at 16 times. It gives $244.93 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $188.11 per share.
The cases give no separate value to the Phase 3 programs of osavampator and direclidine. Intangible assets are the main source of advantage. Under the 2023 settlements, generic INGREZZA can enter the US market from March 1, 2038, or earlier in certain circumstances (2025 10-K). CRENESSITY has seven years of orphan drug exclusivity.
But AUSTEDO competes with INGREZZA, INGREZZA can be selected for Medicare price negotiation in 2027 for prices from 2029, and Alvogen filed for a generic VYKAT XR in September 2026.
As of
Show 4 sourcesHide sources
Checkpoints
- Dec 15, 2026PendingR&D DayNeurocrine gives clear timing for the Phase 3 results of osavampator and direclidine in 2027 and new programs that add value, and this passes; delays of the Phase 3 programs fail.
- Feb 2, 2027 · est.PendingQ4 2026 results and 2027 guidance2026 INGREZZA sales are within $2.900 to $2.925 billion and the 2027 guidance shows growth after the new AUSTEDO Medicare price, and this passes; a miss or a 2027 decline fails.
- 2027 · est.PendingPhase 3 results of osavampator and direclidineAt least one of the two Phase 3 programs meets its main goal in 2027, and this passes; two failures fail.
Recent events
- November 2, 2026Neurocrine reported Q3 2026 results. Total revenue grew 41% to $1,123 million. INGREZZA sales were $801 million (up 17%), CRENESSITY $211 million and VYKAT XR $107 million. Neurocrine raised its 2026 INGREZZA guidance to $2.900 to $2.925 billion and set an R&D Day for December 15, 2026.
- September 25, 2026Eiry W. Roberts, M.D., the former Chief Medical Officer, rejoined the executive team as Chief Medical Officer.
- July 30, 2026Neurocrine reported Q2 2026 results. Total revenue grew 39% to $959 million, and it raised its 2026 INGREZZA guidance to $2.825 to $2.875 billion.
Show 5 older eventsHide older events
- May 18, 2026Neurocrine completed the purchase of Soleno Therapeutics for about $2.9 billion in cash and added VYKAT XR. It recorded about $2.2 billion of VYKAT XR rights, which it amortizes over 16 years.
- May 14, 2026Neurocrine entered into a senior secured revolving credit facility of $1.0 billion. It borrowed $600 million for the Soleno purchase and repaid it in June 2026.
- May 5, 2026Neurocrine reported Q1 2026 net product sales of $811.0 million, up 44%. INGREZZA sales were $656.9 million and CRENESSITY sales were $153.3 million.
- April 5, 2026Neurocrine agreed to buy Soleno Therapeutics for $53.00 per share in cash, through a tender offer.
- February 11, 2026Neurocrine reported 2025 net product sales of $2.83 billion, up 22%. INGREZZA sales were $2.51 billion and CRENESSITY sales were $301.2 million. It guided 2026 INGREZZA sales to $2.7 to $2.8 billion.
Latest news and filings
- Last earnings
- November 2, 2026 (8-K on sec.gov)
- Next earnings
- Expected about February 2, 2027. The company has not confirmed the date.
- 10-QQuarterly report for the period ended Sep 30, 2026Filed nbix-20260930
- 8-KEarnings releaseFiled Press release and exhibits
- 8-KChange of directors or officersFiled nbix-20260925
- 10-QQuarterly report for the period ended Jun 30, 2026Filed nbix-20260630
- 8-KEarnings releaseFiled Press release and exhibits
- 8-KChange of directors or officers and Shareholder vote resultsFiled nbix-20260527
- 8-KNew material agreement and Acquisition or sale completedFiled Read it on sec.gov
- 10-QQuarterly report for the period ended Mar 31, 2026Filed nbix-20260331
- 8-KEarnings releaseFiled Press release and exhibits
- 8-KNew material agreementFiled Read it on sec.gov
Risks
- INGREZZA was about 71% of revenue in Q3 2026. INGREZZA can be selected for Medicare price negotiation in 2027, with a new price from 2029, and the negotiated price of AUSTEDO from 2027 can add price pressure.
- Under the 2023 patent settlements, generic INGREZZA can enter the US market from March 1, 2038, or earlier in certain circumstances. In September 2026, Alvogen filed for approval of a generic VYKAT XR, and Neurocrine sued it.
- The Phase 3 programs of osavampator and direclidine can fail. Neurocrine guides 2026 GAAP R&D of $1,275 to $1,325 million.
- VYKAT XR must grow to justify its price of about $2.9 billion. A class action filed on March 6, 2026 against Soleno and its management is still open.
- Cash and marketable securities fell to $790 million at September 30, 2026, from $2,543 million at the end of 2025, after the Soleno purchase.
Key statistics
- Market cap
- $15B
- Shares of Oct 26, 2026
- P/E (trailing)
- 22.3
- Price of Nov 20, 2026
- EPS (trailing)
- $6.74
- 12 months to Sep 30, 2026
- 52-week range
- $122.14 – $186.12
- To Nov 13, 2026
- Beta
- 0.36
- Vs S&P 500, 5 years monthly, to Oct 30, 2026
- Average volume
- 1.3M
- 3 months, to Nov 13, 2026
Check the numbers:ExchangeGoogle FinanceYahoo FinanceSEC filings
Balance sheet
- Cash
- $790M
- Debt
- $0.0M
- Net cash
- $790M
- Credit line
- $1.0B
- undrawn, to May 2031
Cash against debt
debt covered by cash
At September 30, 2026, Neurocrine had cash, cash equivalents and marketable securities of $790 million, down from $2,543 million at December 31, 2025, because it paid about $2.9 billion in cash for Soleno in May 2026. It had no borrowings. The senior secured revolving credit facility of $1.0 billion was fully available and matures on May 14, 2031. Its covenants set a maximum total net leverage ratio of 3.75 times and a minimum interest coverage of 2.00 times. Total assets were $5,627.4 million and stockholders' equity was $3,878.7 million. $174.2 million remained under the 2025 share repurchase program.
Dividends
Neurocrine Biosciences does not pay a dividend.
Source: company filings and market data, read on November 13, 2026.
Questions about Neurocrine Biosciences
What does Neurocrine Biosciences do?
Neurocrine Biosciences (NBIX) is a US biopharmaceutical company that develops and sells medicines for neurological, psychiatric and endocrine disorders. INGREZZA (valbenazine) treats tardive dyskinesia and chorea associated with Huntington's disease. Its market cap is $15B at the current price of $150.57.
When does Neurocrine Biosciences report earnings next?
This is an estimate: Neurocrine Biosciences may report on February 2, 2027. It last reported results on November 2, 2026.
Is Neurocrine Biosciences stock below its intrinsic value?
Neurocrine Biosciences stock is below intrinsic value. The source of the intrinsic value is: AI estimate. This is general information, not advice.
What changed recently at Neurocrine Biosciences?
The latest update is from November 2, 2026. Neurocrine reported Q3 2026 results.
What are the main risks for Neurocrine Biosciences?
INGREZZA was about 71% of revenue in Q3 2026. Under the 2023 patent settlements, generic INGREZZA can enter the US market from March 1, 2038, or earlier in certain circumstances. The Phase 3 programs of osavampator and direclidine can fail.
How much debt and cash does Neurocrine Biosciences have?
At September 30, 2026, Neurocrine Biosciences had $0.0M of debt and $790M of cash.
Does Neurocrine Biosciences pay a dividend?
No. Neurocrine Biosciences does not pay a dividend.
Valuation against peers
| Company | P/E, last 4 quarters | EV/EBITDA, last year | Free cash flow yield, last year | 10-year average P/E |
|---|---|---|---|---|
| NBIXNeurocrine Biosciences | 22.3x | n/a | 4.9% | 40.7x |
| ALNYAlnylam Pharmaceuticals | 7.5x | n/a | 2.4% | n/a |
| JAZZJazz Pharmaceuticals | 68.1x | n/a | 8.8% | 20.0x |
| BBIOBridgeBio Pharma | n/a | n/a | -3.0% | n/a |
| UTHRUnited Therapeutics | 20.9x | n/a | 4.4% | 12.5x |
| Peer median | 20.9x | n/a | 3.4% | n/a |
- NBIX trades at 22.3x earnings, 7% above the peer median of 20.9x.
- Its free cash flow yield is 4.9%, 1.5 points above the peer median of 3.4%.
- Against its own history, the P/E is 45% below its average of 40.7x over 5 profitable years.
The peers are the companies on this site most like NBIX. The multiples come from company filings and today's price. There are no analyst forecasts: they all look back. EV/EBITDA is left out for banks, insurers and real estate companies. This is general information, not advice.
Similar companies
- ASNDAscendis PharmaShares: Regulation and courts
- Intrinsic value
- Below intrinsic value (AI estimate)
- Gap
- Can close
- ARGXargenxShares: Regulation and courts
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
- ALNYAlnylam PharmaceuticalsShares: Regulation and courts
- Intrinsic value
- Far below intrinsic value
- Gap
- Can close
- ICLRICONShares: Regulation and courts
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
- JAZZJazz PharmaceuticalsShares: Regulation and courts
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
Loading your notes…
Read it all? Star NBIX or pass, then go on to the next one.